Market Intelligence, Clinical Progress, and High-Purity Reagents for Stromal-Targeting and ADC Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TEM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TEM1/CD248 ECD-Fc recombinant protein. High purity (>95%), Endotoxin controlled (<1 EU/ug). Sequence Verified. HEK293 expressed for native glycosylation. | View TEM1 Products |
| Gene Delivery | TEM1/CD248 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction and conformation-dependent binder screening. | View TEM1 Products |
| Benchmark Ab | Anti-TEM1/CD248 Recombinant Antibody (Ontuxizumab sequence). Recombinant positive control for binding and internalization assays. | View TEM1 Products |
| Validator | TEM1/CD248 siRNA Set. For target knockdown verification and functional assay validation. | View TEM1 Products |
| Related Target A | FAP (Fibroblast Activation Protein). Co-expressed with TEM1 on tumor-associated fibroblasts; highly relevant for dual-targeting or combination stromal therapies. | View FAP Products |
| Related Target B | PDGFRB (Beta-type platelet-derived growth factor receptor). Co-marker for pericytes and activated stromal cells involved in tumor angiogenesis. | View PDGFRB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus TEM1 ortholog proteins available with >95% purity to confirm cross-reactivity. |
| Conformation-dependent screening | Lentiviral vectors optimized for high-expression stable cell line generation, preserving native 3D structure. |
| Lack of Controls | Recombinant Benchmark Antibodies (Ontuxizumab sequence) included as functional assay positive controls. |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown validation. |
Live TEM1/CD248 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TEM1/CD248 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies (mAbs) to next-generation Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cells, and Radionuclide Drug Conjugates (RDCs). As first-generation therapies like Ontuxizumab demonstrated that simple blocking of TEM1-mediated signaling yields limited monotherapy clinical efficacy, the next wave of R&D is targeting TEM1 as an anchor for selective payload delivery directly to the tumor microenvironment (TME), specifically targeting tumor-associated pericytes and cancer-associated fibroblasts (CAFs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Innate Pharma, Academic Institutions | Sarcomas, Ovarian Cancer, Triple-Negative Breast Cancer | Internalization Assay (Need high-purity, natively folded ECD-Fc proteins for kinetic binding and uptake assays) |
| CAR-T / Cell Therapy | University of Pennsylvania, Biotech Startups | Solid Tumors (Glioma, Melanoma) | FACS-based binding validation (Need Lentivirus for stable cell line expression of native TEM1 target) |
| Radionuclide Conjugates (RDC) | Translational Research Consortia | Neovascularized Solid Tumors | High-affinity screening & biodistribution profiling (Need cross-reactive Human/Mouse/Cyno proteins) |